A New Approach to Endometriosis: ENDO-205 Enters Clinical Trials

Endometriosis has long been treated as a symptom-management problem. Now, a new drug candidate is trying to change that narrative entirely. EndoCyclic Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for ENDO-205. Translation: The drug is officially moving into human trials.

What Happens Next: Phase 1 Begins?

With IND clearance secured, the company will now:

• Launch a Phase 1 clinical trial
• Study healthy pre-menopausal women
• Evaluate:
  • Safety
  • Tolerability
  • Early pharmacological signals

This is the first real test in humans.

Why This Drug Is Different?

Most current treatments for endometriosis rely on one thing: Hormonal suppression

That approach comes with trade-offs:

• Temporary symptom relief
• Recurrence after stopping treatment
• Side effects from hormone manipulation

ENDO-205 takes a completely different route.

Its core promise:

• Non-hormonal therapy
• Targets endometriosis lesions directly
• Aims to eliminate disease tissue, not just manage symptoms

If it works, this is not incremental. It’s a category shift.

The Science Behind ENDO-205

ENDO-205 is built on a precision peptide platform. What that means in practice:

• Designed to act only on diseased tissue
• Avoids:
  • Hormonal disruption
  • Broad immune suppression
  • Systemic toxicity

Preclinical findings:

• Elimination of endometriosis lesions
• Reduction in inflammation
• No safety signals in GLP toxicology studies

Important caveat: Preclinical success ≠ clinical success But it’s a strong starting point.

Backing and Validation: Not Just Hype

This program isn’t coming out of nowhere. It has:

• Multiple grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development
• Recognition as an NIH SBIR Success Story
• A rare perfect impact score (10/10) in an NIH commercialization grant

The company is also part of the Milken Institute Women's Health Network. Translation: Strong scientific and institutional validation.

The Problem It’s Trying to Solve

Endometriosis is:

• Affects ~10% of women of reproductive age
• Impacts 190+ million globally
• A leading cause of infertility

Symptoms go beyond pain:

• Chronic pelvic pain
• Inflammation
• Systemic complications
• Reduced quality of life

And here’s the real issue: Current treatments don’t eliminate the disease They manage symptoms, but:

• Lesions persist
• Recurrence is common
• Surgery is often inevitable

The Bigger Opportunity

Endometriosis is one of the most underserved areas in medicine. Despite its scale:

• Limited innovation
• Heavy reliance on legacy hormonal therapies
• Diagnostic delays (often years)

ENDO-205 is part of a broader shift: Moving toward targeted, disease-modifying treatments

Beyond Treatment: A Diagnostic Angle

EndoCyclic is also developing:

• FemLUNA (investigational imaging agent)

Goal:

• Detect endometriosis non-invasively
• Potentially replace diagnostic laparoscopy

If successful, this could reshape both diagnosis and treatment pathways.

Final Take

This is very early-stage—but strategically important.

What’s compelling:

• First-in-class, non-hormonal approach
• Targets underlying disease biology
• Strong preclinical data
• Backed by credible institutions

What’s uncertain:

• Will lesion elimination translate in humans?
• Can safety hold at clinical doses?
• Will efficacy beat existing hormonal therapies?

Bottom Line

ENDO-205 represents a bold attempt to solve a problem the industry has mostly worked around.

• Not just managing endometriosis
• But potentially eliminating it at the source

If that holds up in clinical trials, this won’t just be a new drug— It will redefine the standard of care.